Neutrophilic dermatoses comprise a heterogeneous group of disorders, which are characterized by inflammatory skin lesions that share a common histopathological feature, intense inflammatory infiltration consisting primarily of neutrophils, with no evidence of vasculitis. We describe a 75-year-old man with rheumatoid arthritis, who presented with erythematous edematous plaques. The histopathological findings indicated neutrophilic dermatosis; however, the patient was afebrile and without an elevated white blood cell count or systemic involvement. We think that the most suitable expression for this variant with clinical manifestations different from those of classical Sweet syndrome is "chronic recurrent annular neutrophilic dermatosis," as introduced by Christensen et al. 
Introduction
The term "chronic recurrent annular neutrophilic dermatosis (CRAND)" was first used by Christensen et al 1 in 1989 to refer to the skin lesions of two patients who had chronically recurring outbreaks of generalized annular erythematous, edematous cutaneous plaques with histopathological findings suggestive of Sweet syndrome, but without fever or systemic signs and symptoms.
Case Report
We describe a 75-year-old man with a 10-year history of rheumatoid arthritis (RA) who presented to our clinic with recurrent outbreaks of edematous, infiltrated, annular, erythematous plaques with a violaceous center. The lesions first appeared~3 years before admission, were located on the patient's trunk, arms, legs, neck, and scalp (Figures 1Ae1C), and lasted for 3 weeks. The family history was negative for similar conditions. Upon admission, the patient was afebrile, and did not have malaise, myalgia, or lymphadenopathy. He had been taking nonsteroidal antiinflammatory drugs for RA for 10 years. A complete blood count revealed anemia of chronic disease, and the results of routine biochemical testing were normal. His C-reactive protein level was 81 mg/L (reference range, 0e5 mg/L) and erythrocyte sedimentation rate was 71 mm/h (reference range, <20 mm/h). Chest radiography revealed sequelae of tuberculosis in both pulmonary apices. Abdominal ultrasound showed a solid intravesical bladder mass. The histopathological findings of a biopsy of the mass were consistent with papillomatous hyperplasia. Serological testing for evidence of infection with hepatotropic viruses, human immunodeficiency virus, and syphilis was negative. No other serological testing was performed. The patient was negative for the tumor markers prostate-specific antigen, carcinoembryonic antigen, and cancer antigen-19.9, and his stool was negative for occult blood. Serum immunoelectropheresis findings were also normal. Together with the patient's physical examination and history, the clinical assessment was negative for an underlying malignancy, and no additional investigations for the presence of an underlying malignant tumor were performed.
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A skin biopsy specimen showed neutrophilic infiltrate in the upper and mid-dermis, as well as leukocytoclasis. No vasculitis was observed (Figures 2A and 2B ). Colchicine and dapsone, which inhibit neutrophil chemotaxis, were used to treat the infiltrate. However, because of the patient's low hemoglobin level and the occurrence of diarrhea, they were discontinued. The lesions were attributed to poorly controlled RA, and the patient was referred to a rheumatologist, who prescribed methylprednisolone (10 mg/d) and methotrexate (10 mg/wk) for 2 months. The lesions gradually disappeared. However, the patient stopped taking the methylprednisolone and methotrexate because he was worried about the side effects. Two weeks after the treatment was stopped, the lesions reappeared. At a 6-month follow-up visit, the patient complained of severe arthralgia and widespread lesions involving his entire body. He again refused systemic treatment with methylprednisolone and methotrexate. associated with RA, as in our patient. They obtained a successful outcome using dapsone plus colchine to prevent additional recurrences over a 2-year follow-up period. CRAND is a very rare condition; to the best of our knowledge, only five cases have been reported to date. Since no association has been found with drugs, infections, or systemic illness, its etiology remains unknown. 5 It is clinically characterized by recurrent outbreaks of indurated annular plaques with erythematous borders and a violaceous center. Fever, generalized symptoms such as malaise and myalgia, leukocytosis, and neutrophilia are absent. The histopathological findings include neutrophilic infiltration in the mid and upper dermis, leukocytoclasia, and no signs of vasculitis.
4,5
The one case of RA-associated CRAND reported by Mir-Bonaf e et al 5 did not appear to manifest flare ups of CRAND linked to exacerbations of RA. We initially thought that the exacerbations of the lesions of our patient were associated with poorly controlled RA, and the rheumatologist who saw the patient prescribed systemic methotrexate and methylprednisolone. The lesions disappeared 2 weeks after the start of treatment and reappeared after the cessation of treatment. We observed that the appearance of the lesions was associated with worsening arthralgia. RA skin manifestations can be either specific or nonspecific. The specific manifestations include subcutaneous nodules (classical rheumatoid nodules, accelerated rheumatoid nodules, or rheumatoid nodulosis), rheumatoid vasculitis, granulomatous dermatitides (interstitial granulomatous dermatitis or palisaded neutrophilic granulomatous dermatitis), and neutrophilic dermatosis (pyoderma gangrenosum, Sweet syndrome, rheumatoid neutrophilic dermatitis, neutrophilic dermatitis of the dorsal hands, pyogenic sterile arthritis, pyoderma gangrenosum, acne syndrome/synovitis, acne, pustolosis, hyperostosis, osteomyelitis syndrome). 6 RA-associated neutrophilic dermatosis has been linked to mutations in the genes regulating innate immunity, which can induce inflammasome-mediated neutrophil recruitment. 7, 8 Sweet syndrome is rarely seen in patients with RA, and is characterized histopathologically by a neutrophilic infiltrate in the superficial derma and clinically by the sudden onset of fever, an elevated white blood cell count, and erythematous, tender skin lesions. 9 Rheumatoid neutrophilic dermatosis presents with papules, erythematous plaques, nodules, and urticarial lesions with typical symmetric distributions on the joints, extensor surfaces of the extremities, and the trunk. Histopathological findings include neutrophilic infiltrate in the dermis without vasculitis. The lesions of our patient most closely resembled those of patients with Sweet syndrome, except for the recurrent and annular nature of the lesions and absence of constitutional signs and symptoms such as fever and myalgia. We included rheumatoid neutrophilic dermatosis in the differential diagnosis, but our patient's lesions were edematous plaques instead of polymorphic lesions or pustules, and were distributed widely instead of confined to the joints or extensor surfaces of the extremities. 10 In conclusion, we described a rare case of a patient with RA who developed a neutrophilic dermatosis with an atypical, chronic, and recurrent presentation. We think that "CRAND," a descriptive term first used by Christensen et al, 1 to be the most appropriate name for this dermatological manifestation accompanied by clinical findings different from those of classic Sweet syndrome. We suggest that this is a new entity of RA-associated neutrophilic dermatosis, presenting as recurring lesions that worsen with the exacerbation of RA.
Additional studies of large series of similar cases can help us clarify whether or not CRAND is a new type of RA-associated neutrophilic dermatosis.
